S2-E44.4 - COVID-19 and Fatty Liver - What Impact Will the Delta Variant Have On Clinical Trials?
Send us a text Donna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021. This conversation focuses on the current and potential impact of the Delta and future variants on clinical trial performance. Seventeen months ago, Surfing the NASH Tsunami began as a podcast focused on how COVID-19 and the pandemic would affect NASH clinical trials. Some 90 original episodes later, we return to this subject in this conversation. Roger ...
5 Syys 202111min
S2-E44.3 - COVID-19 And Fatty Liver - Areas for Confusion and Policy Discord
Send us a text Donna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021. This conversation focuses on vaccine confusion (taking the flu vaccine, the meaning of full approval) and the importance of global COVID-19 vaccine equity and policies that support it. This conversation has several moments of debate, one around the likely strength of flu season in the US and another around how strong the impact of Pfizer/BioNTech's full FDA impact i...
5 Syys 202113min
S2-E44.2 - COVID-19 And Fatty Liver - Lessons from Immunocompromised Patients and Other Countries
Send us a text Donna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021. This discussion focuses on the case for post-jab immunologic testing for compromised patients and goes on to explore what the US can learn from the UK's experience with the COVID-19 vaccine. Donna Cryer starts this episode by discussing the vital importance of conducting post-vaccine immunologic testing in immunocompromised and liver transplant patients. As St...
4 Syys 202113min
S2-E44.1 - COVID-19 And Fatty Liver --How Immunocompromised and Transplant Patients Became A Priority for Booster Doses
Send us a text Donna Cryer joins the Surfers to discuss how the COVID-19 Delta Variant is affecting Fatty Liver Disease in 2021. This discussion focuses on the process of moving immunocompromised and transplant patients to the front of the booster dose queue. After Roger Green sets the preamble for this discussion of COVID-19 Delta variant and Fatty Liver Disease, Donna Cryer kicks the discussion off by discussing how immunocompromised and liver transplant patients, who had low priority for t...
4 Syys 202114min
S2-E44 - The impact Of the COVID-19 Delta Variant on NAFLD and NASH
Send us a text Donna Cryer joins the Surfers to discuss the different effects that the Delta Variant of COVID-19 is having on different stakeholders within the Fatty Liver community. What impact is the Delta Variant of COVD-19 having on NAFLD and NASH? Let us count the ways in this lively, fast-paced episode with Donna Cryer and the Surfers: 16:11 - Global Liver Institute's efforts to drive priority vaccine position for transplant and severely immunocompromised liver patients 22:12 - Creating...
2 Syys 20211h 2min
S2-E43.4 -Rethinking Cirrhosis: A Call To Action
Send us a text Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation constitutes a call to action for the Surfers and our listeners. In terms of cirrhosis and drug development, the earlier conversations identified two goals: Focus on NASH cirrhosis as a possible an easier and faster path to approval than the traditional "start with F2/3" approach, and push to move the codification of disease knowledge and best practices from guidance documents t...
29 Elo 202111min
S2-E43.3 - Driving A Reconsideration Of Cirrhosis In Drug Development
Send us a text Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on how to drive a broader change in perspective. Once we accept the idea that cirrhosis can make an excellent target for drug development driven using non-invasive testing, the question is take the lead in bringing the appropriate initiative forward. Stephen Harrison points out that principal investigator KOLs are the group with the most knowledge and perspective but later no...
29 Elo 202112min
S2-E43.2 - Rethinking Cirrhosis As A Target For Drug Development
Send us a text Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on why F4 might be a better target than F2/3. This conversation focuses on specific reasons that initiating drug development in cirrhosis might offer unique benefits against the traditional model. Stephen Harrison starts off by discussing changing views of which cirrhosis patients are mostly likely to respond. After some comments from Louise Campbell about patient engagement,...
28 Elo 202111min
